LenioBio secures EUR 3.7M of EU4Health funding to develop ALiCE® for cost-effective and rapid production of protein-based medicines

LenioBio Germany

 and follow LenioBio on LinkedIn.

About EU4Health, HaDEA and HERA

The European Health and Digital Executive Agency (HaDEA) implements the vast majority of the EU4Health programme by managing calls for proposals and tenders from 2021 to 2027. The programme and its calls represent an ambitious response to the COVID-19 pandemic, but go beyond crisis response to address the resilience of European healthcare systems and contribute to a healthier Europe.  EU4Health funds actions that include increasing the availability, accessibility, and affordability of medicines and medical products, boosting preparedness for cross-border health threats, and advancing innovation in healthcare. Learn more here (https://health.ec.europa.eu/funding/eu4health-programme-2021-2027-vision-healthier-european-union_en)

The European Commission's Health Emergency Preparedness and Response Authority (HERA) was established in response to lessons learned from the COVID-19 pandemic. HERA supports projects that strengthen the EU's capacity to prevent, detect, and respond to serious health emergencies, ensuring the timely availability of critical medical countermeasures. Learn more here (https://health.ec.europa.eu/health-emergency-preparedness-and-response-hera_en)

Media Contact:

Akanksha Ranjit
Marketing & Communications
LenioBio GmbH
[e-mail]

Photo - https://mma.prnewswire.com/media/2735876/LenioBio_Health_Grant.jpg
Logo - https://mma.prnewswire.com/media/2735875/LenioBio_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/leniobio-secures-eur-3-7m-of-eu4health-funding-to-develop-alice-for-cost-effective-and-rapid-production-of-protein-based-medicines-302511105.html